hENT1 protein expression level is strongly correlated with patient outcomes and drug sensitivity in cancer therapies that utilize nucleoside analogs such as cytarabine (e.g., leukemia or lymphoma) or gemcitabine (e.g., pancreatic or lung cancer) [4,60,61,62,63,64,65,66,67]. This evidence concerns the gene SLC29A1 and lung carcinoma.